Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-PSMA-11 PET in Prostate Cancer
NCT05197257Phase 3Completed
- Sponsor
- University of Colorado Denver
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by University of Colorado Denver. Primary endpoint: Number of Participants With Adverse Events at 1.5 hours. Started Sep 2021; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05197257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197257.